Clinical

Dataset Information

0

A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.


ABSTRACT: This is a clinical study with an orally administered drug, BDTX-189 in participants with advanced solid tumors that have select mutations or alterations in human epidermal growth factor receptor 2 (HER2/ErbB2) genes or epidermal growth factor receptor (EGFR/ErbB1). The main goals of this study are to: * Find the recommended dose of BDTX-189 that can be given safely to participants * Learn more about the side effects of BDTX-189 * Learn what the body does to BDTX-189 after it has been taken (pharmacokinetics or PK) * Determine the antitumor activity of BDTX-189 in participants with select allosteric ErbB gene mutations

DISEASE(S): Endometrial Cancer,Lung Cancer,Solid Tumor,Nsclc, Breast Cancer, Biliary Tract Cancer, Or Cervical Cancer, Any Other Solid Tumors With Specific Gene Mutations,Colon Cancer,Colorectal Cancer,Non-small Cell Lung Cancer,Gastric Cancer,Bladder Cancer,Breast Cancer

PROVIDER: 2325490 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| PRJNA117241 | ENA
| 2731194 | ecrin-mdr-crc
2023-03-11 | PXD037374 | Pride
2016-09-11 | GSE72928 | GEO
| 2067836 | ecrin-mdr-crc
| PRJNA1157847 | ENA
| 2184006 | ecrin-mdr-crc
| 2399513 | ecrin-mdr-crc
2023-03-11 | PXD037448 | Pride
| 2042264 | ecrin-mdr-crc